Returns may suffer as drugmakers compete in crowded cancer field

January 7, 2014 3:16 PM

28 0

Pharmaceutical companies including Switzerland's Novartis and Roche are among those developing a treatment for a specific type of lung cancer, a field that is now so crowded it may impact profits.

A better understanding of the cause of tumors has drawn resources into cancer research at the expense of antibiotics and cardiovascular disease but over-concentration in certain fields could cut commercial rewards, some analysts say.

Read more

To category page